Shuaibin Liu
Chongqing, 400010, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Corrigendum to 'Recombinant humanized type III collagen inhibits ovarian cancer and induces protective anti-tumor immunity by regulating autophagy through GSTP1' [Mater. Today Bio. 2024 Sep 1; 28: 101220].
Journal: Materials today. Bio
Published: February 02, 2026
Recombinant humanized type III collagen inhibits ovarian cancer and induces protective anti-tumor immunity by regulating autophagy through GSTP1.
Journal: Materials today. Bio
Published: June 06, 2024
Recombinant humanized collagen remodels endometrial immune microenvironment of chronic endometritis through macrophage immunomodulation.
Journal: Regenerative biomaterials
Published: December 15, 2022
Injectable recombinant human collagen-derived material with high cell adhesion activity limits adverse remodelling and improves pelvic floor function in pelvic floor dysfunction rats.
Journal: Biomaterials advances
Published: September 06, 2021
Intravaginal Administration of Human Type III Collagen-Derived Biomaterial with High Cell-Adhesion Activity to Treat Vaginal Atrophy in Rats.
Journal: ACS biomaterials science & engineering
Published: January 18, 2021
Erratum: DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.
Journal: Oncology letters
Published: September 23, 2020
Erratum: DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.
Journal: Oncology letters
Published: March 21, 2020
DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.
Journal: Oncology letters
Published: October 06, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026